Longitudinal Blood-Based Biomarkers and Clinical Progression in Subjective Cognitive Decline

Are longitudinal changes in blood-based biomarkers associated with cognitive decline and clinical progression in individuals with subjective cognitive decline (SCD)?In this cohort study of 298 individuals with SCD, steeper slopes of plasma phosphorylated tau 217 (pTau 217), glial fibrillary acidic protein (GFAP), and neurofilament light were associated with cognitive decline, whereas pTau217 and GFAP slopes were associated with progression to mild cognitive impairment or dementia. One in 5 of the initially biomarker-negative participants transitioned to a biomarker-positive status during follow-up.This study’s results suggest that longitudinal changes in pTau217 and GFAP are promising blood-based biomarkers for early identification and monitoring of Alzheimer disease progression in individuals with SCD.

Corresponding Author: Calvin Trieu, MD, Alzheimer Center Amsterdam, De Boelelaan 1118, 1081 HV Amsterdam (c.trieu@amsterdamumc.nl).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.